Theradiag Announces Its 2023 Half-Year Results and Reports a Significant Improvement in Profitability

Regulatory News:

THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced its half-year results to June 30, 2023, as approved by the Board of Directors on September 14, 2023.

2023 Half-year results

In thousands of euros	H1 2023	H1 2022	% change
Revenue	6,701	6,264	+7.0%
of which: Theranostics	3,569	3,027	+17.9%
of which: IVD	3,132	3,236	-3.2%
Operating profit/(loss)	835	-129	NA
Income/(loss) before tax and non-recurring items	793	-173	NA
Net income/(loss) before non-recurring items	921	-56	NA
Net-recurring items	-67	0	NA
Net income/(loss)	853	-56	NA

Simon DAVIERE, CEO of Theradiag, commented: "In the first half of 2023, the company reported good profitability, with an operating margin of 12.5%. The achievement of this level of profitability is the result of the efforts made by all our teams, whom I would like to thank, of Theradiag unique historical positioning in the biotherapy monitoring market, and of the strategic choices made in recent half-years, including the strategic reorientation carried out in the United States. In the coming months, Theradiag will focus on continuing to deploy its profitable growth and developing synergies with its majority shareholder, Biosynex."